Table 2.

Variables associated with progression-free survival (PFS) in the univariate analysis.

	PFS
Variables	HR (95% CI)		P-value
Age (≥60 vs. <60)	1.158 (0.614–2.185)		0.651
Gender (male vs. female)	1.428 (0.776–2.626)		0.252
B symptoms (presence vs. absence)	0.891 (0.347–2.289)		0.810
Histologic grade (3A vs. 1 to 2)	1.375 (0.724–2.613)		0.331
Bone marrow involvement (presence vs. absence)	1.430 (0.778–2.629)		0.249
Ann Arbor stage (III to IV vs. I to II)	2.124 (0.831–5.428)		0.116
LDH (normal vs. elevated)	4.861 (2.495–9.472)		<0.001
β2-MG (normal vs. elevated)	4.009 (2.167–7.418)		<0.001
Hb (g/dl) (<12 vs. ≥12)	1.863 (1.017–3.416)		0.044
Platelet count (<150 × 109/L vs. ≥150 × 109/L)	1.747 (0.927–3.291)		0.081
Number of nodal sites (>4 vs. 0–4)	1.583 (0.820–3.058)		0.171
LodLIN (cm) (>6 vs. ≤6)	1.702 (0.880–3.290)		0.114
SUVmax (>17.60 vs. ≤17.60)	2.983 (1.566–5.681)		<0.001
TMTV (>408.72 cm3 vs. ≤408.72 cm3)	4.622 (2.450–8.717)		<0.001
TLG (>1,446.98 vs. ≤1,446.98)	6.736 (3.324–13.650)		<0.001
D max (>56.73 cm vs. ≤56.73 cm)	6.344 (2.484–16.200)		<0.001
FLIPI			0.011
Low risk	Reference
Intermediate risk	1.330 (0.498–3.552)		0.570
High risk	2.966 (1.207–7.289)		0.018
FLIP2			0.052
Low risk	Reference
Intermediate risk	1.934 (0.729–5.136)		0.185
High risk	3.182 (1.164–8.702)		0.024
PRIMA-PI			<0.001
Low risk	Reference
Intermediate risk	1.416 (0.568–3.530)		0.455
High risk	3.939 (1.911–8.120)		<0.001

LodLIN, longest diameter of the largest node; Hb, hemoglobin; LDH, lactate dehydrogenase; β2-MG, β2-microglobulin; SUV, standardized uptake value; TMTV, total metabolic tumor volume; TLG, total lesion glycolysis; D_max, the largest distance between two lesions; FLIPI, Follicular Lymphoma International Prognostic Index; PRIMA-PI, PRIMA-Prognostic Index.